PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Tilray Brands, Inc. (TLRY.TO)
2.000.05 (2.56%)
1.90 - 2.15
0.48 - 2.54
9.88M / 3.06M (Avg.)
-0.59 | -3.40
Helps investors judge whether earnings growth is driven by sustainable operations or temporary factors. Consistent, organic income expansion can justify a higher intrinsic value for patient, long-term investors.
-11.93%
Revenue decline while Drug Manufacturers - Specialty & Generic median is -0.42%. Seth Klarman would investigate if market share loss is temporary.
-10.66%
Cost reduction while Drug Manufacturers - Specialty & Generic median is 3.43%. Seth Klarman would investigate competitive advantage potential.
-15.04%
Gross profit decline while Drug Manufacturers - Specialty & Generic median is -11.18%. Seth Klarman would investigate competitive position.
-3.53%
Margin decline while Drug Manufacturers - Specialty & Generic median is -3.53%. Seth Klarman would investigate competitive position.
41.67%
R&D change of 41.67% versus flat Drug Manufacturers - Specialty & Generic spending. Walter Schloss would verify adequacy.
-14.24%
G&A reduction while Drug Manufacturers - Specialty & Generic median is 0.00%. Seth Klarman would investigate efficiency gains.
-13.96%
Marketing expense reduction while Drug Manufacturers - Specialty & Generic median is -1.48%. Seth Klarman would investigate competitive implications.
1416.14%
Other expenses change of 1416.14% versus flat Drug Manufacturers - Specialty & Generic costs. Walter Schloss would verify efficiency.
555.63%
Operating expenses growth exceeding 1.5x Drug Manufacturers - Specialty & Generic median of 28.07%. Jim Chanos would check for waste.
220.71%
Total costs growth exceeding 1.5x Drug Manufacturers - Specialty & Generic median of 8.47%. Jim Chanos would check for waste.
7.88%
Interest expense growth exceeding 1.5x Drug Manufacturers - Specialty & Generic median of 0.29%. Jim Chanos would check leverage.
412.62%
D&A growth exceeding 1.5x Drug Manufacturers - Specialty & Generic median of 1.57%. Jim Chanos would check for overinvestment.
-1411.63%
EBITDA decline while Drug Manufacturers - Specialty & Generic median is -62.63%. Seth Klarman would investigate causes.
-1616.43%
EBITDA margin decline while Drug Manufacturers - Specialty & Generic median is -49.73%. Seth Klarman would investigate causes.
-1383.16%
Operating income decline while Drug Manufacturers - Specialty & Generic median is -42.52%. Seth Klarman would investigate causes.
-1584.11%
Operating margin decline while Drug Manufacturers - Specialty & Generic median is -53.31%. Seth Klarman would investigate causes.
-305.08%
Other expenses reduction while Drug Manufacturers - Specialty & Generic median is -71.06%. Seth Klarman would investigate advantages.
-851.87%
Pre-tax income decline while Drug Manufacturers - Specialty & Generic median is -63.67%. Seth Klarman would investigate causes.
-980.84%
Pre-tax margin decline while Drug Manufacturers - Specialty & Generic median is -99.32%. Seth Klarman would investigate causes.
-40.91%
Tax expense reduction while Drug Manufacturers - Specialty & Generic median is -40.91%. Seth Klarman would investigate advantages.
-825.75%
Net income decline while Drug Manufacturers - Specialty & Generic median is -60.99%. Seth Klarman would investigate causes.
-951.18%
Net margin decline while Drug Manufacturers - Specialty & Generic median is -52.77%. Seth Klarman would investigate causes.
-782.35%
EPS decline while Drug Manufacturers - Specialty & Generic median is -60.99%. Seth Klarman would investigate causes.
-500.00%
Diluted EPS decline while Drug Manufacturers - Specialty & Generic median is -6.78%. Seth Klarman would investigate causes.
5.01%
Share count reduction below 50% of Drug Manufacturers - Specialty & Generic median of 5.01%. Jim Chanos would check for issues.
5.01%
Diluted share reduction below 50% of Drug Manufacturers - Specialty & Generic median of 5.01%. Jim Chanos would check for issues.